Shares of Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the fifteen research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $28.14.
CLYM has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating on shares of Climb Bio in a research report on Monday, October 12th. Robert W. Baird upped their price target on Climb Bio from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Thursday, September 3rd. Guggenheim restated a “buy” rating on shares of Climb Bio in a report on Monday, October 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research note on Thursday, October 15th. Finally, Deutsche Bank initiated coverage on Climb Bio in a research note on Tuesday, October 20th. They issued a “buy” rating and a $28.00 price objective on the stock.
View Our Latest Stock Report on Climb Bio
Climb Bio Stock Performance
Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. On average, analysts predict that Climb Bio will post -0.75 EPS for the current fiscal year.
Insider Activity
In other news, Director Stephen Thomas sold 100,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the transaction, the director directly owned 467,969 shares of the company’s stock, valued at approximately $6,397,136.23. The trade was a 17.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.60% of the company’s stock.
Institutional Trading of Climb Bio
A number of hedge funds have recently made changes to their positions in CLYM. State of Wyoming bought a new position in Climb Bio in the third quarter worth about $31,000. Legal & General Group Plc acquired a new stake in shares of Climb Bio during the second quarter worth $45,000. Spark Investment Management LLC purchased a new stake in Climb Bio during the second quarter valued at about $177,000. Profund Advisors LLC purchased a new stake in shares of Climb Bio in the 3rd quarter valued at approximately $190,000. Finally, Bank of America Corp DE acquired a new stake in Climb Bio during the 2nd quarter worth about $335,000. Institutional investors and hedge funds own 69.76% of the company’s stock.
About Climb Bio
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Recommended Stories
- Five stocks we like better than Climb Bio
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
